MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
The company will start its confirmatory bexobrutideg study in June.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
The oncolytic virus vuso-vec is slapped with its second CRL.
The group impresses in ovarian and endometrial cancers.
Optimum-02 virtually replicates phase 1, and a filing will follow.
